



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
21.04.2021 Bulletin 2021/16

(45) Date of publication and mention
of the grant of the patent:
30.12.2020 Bulletin 2020/53

(21) Application number: **16797166.2**

(22) Date of filing: **17.05.2016**

(51) Int Cl.:
C07K 14/705 ^(2006.01) **C07K 14/55** ^(2006.01)
C07K 16/28 ^(2006.01) **A61K 38/20** ^(2006.01)
A61P 7/06 ^(2006.01) **A61P 9/10** ^(2006.01)
A61P 11/06 ^(2006.01) **A61P 31/12** ^(2006.01)
A61P 35/00 ^(2006.01) **A61P 37/02** ^(2006.01)
A61P 37/06 ^(2006.01) **A61P 37/08** ^(2006.01)
A61P 43/00 ^(2006.01)

(86) International application number:
PCT/US2016/032921

(87) International publication number:
WO 2016/187226 (24.11.2016 Gazette 2016/47)

(54) **SIRP POLYPEPTIDE COMPOSITIONS AND METHODS OF USE**

SIRP-POLYPEPTID-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG
COMPOSITIONS DE POLYPEPTIDE SIRP ET PROCÉDÉS D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **18.05.2015 US 201562163282 P**
11.12.2015 US 201562266450 P

(43) Date of publication of application:
28.03.2018 Bulletin 2018/13

(60) Divisional application:
20216691.4

(73) Proprietor: **AB Initio Biotherapeutics, Inc.**
San Diego, CA 92121 (US)

(72) Inventors:
• **RING, Aaron Michael**
Palo Alto, California 94306 (US)
• **MAUTE, Roy Louis**
San Francisco, California 94103 (US)
• **KRUSE, Andrew Curtis**
Roslindale, Massachusetts 02131 (US)
• **MANGLIK, Aashish**
Menlo Park, California 94025 (US)

• **LIN, Kenneth S.**
Los Altos, California 94023 (US)

(74) Representative: **Mewburn Ellis LLP**
Aurora Building
Counterslip
Bristol BS1 6BX (GB)

(56) References cited:
US-A1- 2010 239 579

• **E SICK ET AL: "CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest", BRITISH JOURNAL OF PHARMACOLOGY, vol. 167, no. 7, 6 November 2012 (2012-11-06), pages 1415-1430, XP055247122, UK ISSN: 0007-1188, DOI: 10.1111/j.1476-5381.2012.02099.x**
• **GARY BROOKE ET AL: "Human Lymphocytes Interact Directly with CD47 Through a Novel Member of the Signal Regulatory Protein (SIRP) Family", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 173, no. 4, 15 August 2004 (2004-08-15), pages 2562-2570, XP008138739, ISSN: 0022-1767**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- JOANNE E NETTLESHIP ET AL.: "Crystal structure of signal regulatory protein gamma (SIRP[gamma]) in complex with an antibody Fab frag", BMC STRUCTURAL BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 13, no. 1, 4 July 2013 (2013-07-04), page 13, XP021156553, ISSN: 1472-6807, DOI: 10.1186/1472-6807-13-13
- HATHERLEY, D ET AL.: 'Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD 47.' MOLECULAR CELL . vol. 31, no. 2, 25 July 2008, pages 266 - 277, XP055175089
- LEE, WY ET AL.: 'Novel Structural Determinants on SIRP alpha that Mediate Binding to CD 47.' THE JOURNAL OF IMMUNOLOGY vol. 179, no. 11, 01 December 2007, pages 7741 - 7750, XP055081468
- STEFANIDAKIS, M ET AL.: 'Endothelial CD 47 Interaction with SIRP gamma is Required for Human T- cell Transendothelial Migration Under Shear Flow Conditions In Vitro.' BLOOD vol. 112, no. 4, 04 June 2008, pages 1280 - 1289, XP055331545